• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Pre- and post-natal Lactobacillus reuteri supplementation decreases allergen responsiveness in infancy
【24h】

Pre- and post-natal Lactobacillus reuteri supplementation decreases allergen responsiveness in infancy

机译：产前和产后罗伊氏乳杆菌补充降低婴儿期的变应原反应性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: We have previously shown that Lactobacillus reuteri supplementation from pregnancy week 36 and to the infant through the first year of life decreased the prevalence of IgE-associated eczema at 2 years. The underlying immunological mechanisms are unknown, however. Objective: To investigate the immunomodulatory effect of probiotic supplementation on allergen- and mitogen-induced immune responses in children until 2 years of age. Methods: Blood mononuclear cells were collected at birth, 6, 12 and 24 months from 61 children (29 probiotic and 32 placebo treated) and cultured with ovalbumin, birch and cat extract and Phytohaemagglutinin (PHA). Cytokine and chemokine secretion was determined using an in-house multiplexed Luminex assay and ELISA. Real-time PCR was performed to investigate the Ebi3, Foxp3, GATA-3 and T-bet mRNA expression. Results: Probiotic treatment was associated with low cat-induced Th2-like responses at 6 months (IL-5, P = 0.01, and IL-13, P = 0.009), with a similar trend for IL-5 at 12 months (P = 0.09). Cat-induced IFN-γ responses were also lower after probiotic than after placebo treatment at 24 months (P = 0.007), with similar findings for the anti-inflammatory IL-10 at birth (P = 0.001) and at 12 months (P = 0.009). At 24 months, Th2-associated CCL22 levels were lower in the probiotic than in the placebo group after birch stimulation (P = 0.02), with a similar trend after ovalbumin stimulation (P = 0.07). Lower CCL22 levels were recorded at 12 and 24 months (P = 0.03 and P = 0.01) after PHA stimulation. Conclusion and Clinical Relevance: Lactobacillus reuteri supplementation decreases allergen responsiveness and may enhance immunoregulatory capacity during infancy. L. reuteri supplementation from week 36 and during the first year of life significantly decreases IgE-associated eczema and lowers allergen and mitogen responsiveness.
机译：背景：我们先前已经证明，从怀孕36周到婴儿至生命的第一年，补充罗伊氏乳杆菌可降低2岁时IgE相关湿疹的患病率。然而，潜在的免疫机制尚不清楚。目的：探讨补充益生菌对2岁以下儿童过敏原和有丝分裂原诱导的免疫反应的免疫调节作用。方法：在出生，6、12和24个月时从61名儿童（29名益生菌和32名安慰剂治疗）中收集血液单核细胞，并用卵清蛋白，桦树和猫提取物以及植物血凝素（PHA）培养。使用内部多重Luminex分析和ELISA测定细胞因子和趋化因子的分泌。进行实时PCR研究Ebi3，Foxp3，GATA-3和T-bet mRNA表达。结果：益生菌治疗与6个月猫诱导的Th2样应答低有关（IL-5，P = 0.01，IL-13，P = 0.009），IL-5在12个月时的趋势相似（P = 0.09）。益生菌治疗后24个月，猫诱发的IFN-γ反应也低于安慰剂治疗（P = 0.007），在出生时和12个月时（P = 0.001）与抗炎性IL-10的发现相似（P = 0.009）。在24个月时，桦木刺激后，益生菌中Th2相关的CCL22水平低于安慰剂组（P = 0.02），卵清蛋白刺激后的趋势类似（P = 0.07）。在PHA刺激后第12和24个月记录到较低的CCL22水平（P = 0.03和P = 0.01）。结论与临床意义：补充罗伊氏乳杆菌可降低过敏原反应性，并可能增强婴儿期的免疫调节能力。从第36周到生命的第一年补充罗伊氏乳杆菌可显着降低与IgE相关的湿疹，并降低过敏原和有丝分裂原的反应性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号